|
業務類別
|
Biotechnology |
|
業務概覽
|
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union. |
| 公司地址
| 655 Third Avenue, Suite 1115, New York, NY, USA, 10017 |
| 電話號碼
| +1 646 860-7985 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.meiragtx.com |
| 員工數量
| 403 |
| Dr. Stuart Naylor, PhD |
Chief Development Officer |
美元 501.17K |
30/04/2025 |
| Dr. Alexandria Forbes, PhD |
President, Chief Executive Officer and Director |
美元 840.00K |
30/03/2026 |
| Dr. Robert K. Zeldin, M.D. |
Chief Medical Officer |
-- |
30/04/2025 |
| Mr. Richard Giroux |
Chief Accounting Officer, Chief Operating Officer and Chief Financial Officer |
美元 714.00K |
30/03/2026 |
| Mr. Robert J. Wollin |
General Counsel and Secretary |
-- |
30/04/2025 |
|
|
| Dr. Thomas E. Shenk, PhD |
Independent Director |
30/03/2026 |
| Ms. Nicole Seligman |
Independent Director |
30/03/2026 |
| Dr. Alexandria Forbes, PhD |
President, Chief Executive Officer and Director |
30/03/2026 |
| Dr. Keith R. Harris, PhD |
Chairman of the Board |
30/03/2026 |
| Dr. Ellen Hukkelhoven, PhD |
Director |
30/03/2026 |
| Lord Neil Mendoza |
Independent Director |
30/03/2026 |
| Dr. Debra Yu, M.D. |
Independent Director |
30/03/2026 |
|
|
|
|
